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Abstract
During the carcinogenesis process, tumour cells often have 
a more rapid proliferation potential than cells that participate 
in blood capillary formation by neoangiogenesis. As a conse-
quence of the poorly organized vasculature of various solid 
tumours, a limited oxygen delivery is observed. This hypoxic 
mechanism frequently occurs in solid cancers and can lead to 
therapeutic resistance. The present selected literature review 
is focused on the comparison of two positron emitting radio-
pharmaceuticals agents, which are currently leaders in tumour 
hypoxia imaging by PET. [18F]-fluoromisonidazole (= FMISO) 
is most commonly used as an investigational PET agent with 
an investigational new drug exemption from the FDA, while 
[64Cu]-diacetyl-bis(N4-methylthiosemicarbazone) (64Cu-ATSM) 
has been presented as an alternative radiopharmaceutical not 
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yet readily available. The comparison of these two radiophar-
maceutical agents is particularly focused on isotope properties, 
radiopharmaceutical labelling process, pharmacological mecha-
nisms, dosimetry data in patients, and clinical results in terms of 
image contrast. PET imaging has demonstrated a good efficacy 
in tumour hypoxia imaging with both FMISO and Cu-ATSM, but 
FMISO has presented too slow an in vivo accumulation and a 
weak image contrast of the hypoxia area. Despite a less favour-
able dosimetry, 64Cu-ATSM appears superior in terms of imaging 
performance, calling for industrial and clinical development of 
this innovative radiopharmaceutical.
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Introduction
During the carcinogenesis process of a wide range of solid 
tumours, tumour cells often have a more rapid proliferation poten-
tial than the cells that form blood capillaries by neoangiogenesis. 
As a consequence of this poorly organized vasculature, a hy-
poxia area is often observed due to the limited delivery of oxygen 
(Figure 1) in a population of cells distant from blood vessels 
(> 100 mm from the closest blood vessel [1]).
Hypoxia in the tumour microenvironment is an extensively 
studied parameter because this lack of oxygen has negative im-
plications for clinical outcome. The effects of hypoxia are related 
to two major events: 1 — hypoxia raises genetic instability and 
more aggressive phenotypes with bad prognosis for patients, 
and 2 — hypoxic cells are more resistant to radiotherapy and 
chemotherapy treatments (consequence of poor vascularization 
[2]). The increased resistance to radiotherapy (Figure 2) has been 
particularly studied in head and neck cancers and cervical carcino-
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mas [3, 4] and is associated with the loss of oxygen enhancement 
effect during radiotherapy. 
The radiobiological mechanism by which ionizing radia-
tions kill cells is mostly based on DNA damage, particularly DNA 
double strand breaks. This damage results from ionization either 
in or very close to the DNA molecule, producing a radical on the 
DNA (DNAŸ). This radical is then engaged either in an oxidation 
process into aerobic cells resulting in permanent damage, or in 
a reduction process into hypoxic cells [5] mostly by thiol-containing 
compounds that can restore DNA and lead to tumour cell survival.
Over the years, several different methods have been developed 
to assess the in vivo hypoxic level of tumours. The polarographic 
oxygen electrode (most commonly known as the “Eppendorf 
electrode”) was used as the gold standard and has been exten-
sively employed for quantifying hypoxia at different positions in 
tumours and within a short time frame in both animal studies and 
human tumours [6, 7]. However, this method presents some 
major drawbacks. It is an invasive technique limited to accessible 
tumours with sufficient size with a risk of tissue disruption and 
is known to present large inter-observer variability [8]. Another in-
vasive method based on biopsy immunohistochemical analysis of 
hypoxia-inducing factors-1a (HIF-1a) is used to investigate the 
hypoxia status of tumours. HIF-1a is the major transcription factor 
of genes that are involved in angiogenesis, glucose metabolism, 
cell proliferation/survival, and invasion/metastasis and was found 
overexpressed in human cancers as a result of intratumoural 
hypoxia [9].
In recent decades, investigations into alternative, non-invasive 
imaging methods for measuring pO2 have been studied [10]. The 
use of positron emission tomography (PET) has led to a number 
of promising positron emitter radiopharmaceuticals [11–13]. The 
purpose of the present selected literature review is focused on 
the comparison of the two positron emitter radiopharmaceutical 
agents which are currently the leaders in PET imaging of tumour 
hypoxia: [18F]-fluoromisonidazole (= [18F]-FMISO) used as a refer-
ence and the innovative [64Cu]-diacetyl-bis(N4-methylthiosemicar-
bazone) (= [64Cu]-ATSM). Among the different tumour hypoxia PET 
radiotracers, we choose these two compounds for the following 
reasons: [18F]-FMISO is the most used radiopharmaceutical in 
this clinical indication, it is also the classical reference for ni-
troimidazole compounds, while ATSM seems to be an innovative 
compound for hypoxia imaging which could be labelled with some 
copper positron emitter radioactive isotopes like 60/61/62/64Cu. The 
metabolism and pharmacological pathway of ATSM-Cu complex 
is the same for all the copper isotopes, and the choice for clinical 
use between these isotopes is based on physical properties. The 
physical and production properties of 60/61/62/64Cu isotopes are 
summarized in Table 1.
Briefly, copper-60, 61, and 62 present too short a half-life for es-
sential wide delivery of routine clinical isotopes in nuclear medicine 
practice. However, copper-62 presents an alternative production 
means by the 62Zn/62Cu generator. The advantage of this generator 
is the half-life of 62Zn (9.2 hours), but the major drawback is the 
small cross section of the 62Zn cyclotron production leading to 
an important production cost which will limit its clinical use. Fur-
Figure 2. Cell survival-curve for aerobic and hypoxic cells.
Table 1. Physical and production properties of positron emitter copper isotopes [14–16]
Copper 
Isotopes
Half-life
Branching ratio 
of b+
Max energy 
of b+ [keV]
Max intrinsic 
resolution 
in tissue [mm]
Nuclear production 
reaction
Energy for max 
cross section [MeV\
Production cross 
section [mbarn]
60Cu 23.7 min 93% 1980.8 9.9 60Ni(p,n)60Cu 12.5 308
61Cu 3.3 h 62% 1215.2 5.1 61Ni(p,n)61Cu 11.0 407
62Cu 9.7 min 98% 2926.0 16.6
62Ni(p,n)62Cu 10.7 1390
63Cu(p,2n) 62Zn ®62Cu 24.5 63
64Cu 12.7 h 18% 653.0 2.2 64Ni(p,n)64Cu 10.6 837
Blood vessel
Tumour cell
Extracellular
matrix
10 mm
Decreasing pO2
Decreasing
chemotherapy
concentration
Figure 1. Hypoxia consequences in tumour cells distant from blood 
vessels.
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Table 2. Physical properties of fluorine-18 and copper-64
Isotopes Half-life Branching ratio of b+
Mean energy of b+ 
[keV]
Max. energy of b+
[keV]
Other emission 
(branching ratio)
18F 109.77 min 100% 249.8 633.05 /
64Cu 12.701 h 17.6% 278.21 653.03
Auger electron (41%) 
g (0.5%) 
b (38.5%)
thermore, copper-60, 61, and 62 present an important b+ energy 
and consequently a poor intrinsic resolution. Despite the fact that 
copper-64 presents a low positron branching ratio (17.6%) and 
relatively poor dosimetric characteristics, for clinical possibilities, in 
this review we focused on 64Cu because this isotope presents the 
best compromise between adapted physical properties (suf-
ficiently long half-life, better intrinsic image resolution with low b+ 
maximal energy) and good production yield (reasonable produc-
tion costs). The main objective of this study is to demonstrate the 
potential clinical role of [64Cu]-ATSM compared to [18F]-FMISO 
in the imaging of tumour hypoxia. To compare [18F]-FMISO and 
[64Cu]-ATSM radiopharmaceuticals agents, we focused in particu-
lar on isotope properties, radiopharmaceutical labelling processes, 
cell hypoxia accumulation pathways, dosimetric data on patients, 
and clinical results in terms of image contrast.
Comparisons of [18F]-FMISO and [64Cu]-ATSM
Isotope properties and production parameters
Both isotopes, fluorine-18 and copper-64, are produced 
by cyclotron irradiation. Fluorine-18 is usually obtained by the 
18O(p,n)18F reaction. A maximum cross section of about 600 mbarn 
is obtained with a proton beam of about 5 MeV [17]. Copper-64 
is mainly obtained by the 64Ni(p,n)64Cu nuclear reaction. This cy-
clotron reaction requires a proton beam of about 11 MeV and 
presents a good production yield with a cross section of about 
700 mbarn [15, 16]. With the ARRONAX cyclotron (a high energy 
and high intensity multi-particle accelerator located in Nantes, 
France) another reaction route, 64Ni (d,2n), is used. The excita-
tion function looks attractive, with a maximum cross section of 
800 mbarn at 16 MeV [18]. Targets are made of enriched 64Ni 
(more than 96%) electroplated onto gold backing. Since 64Ni 
is expensive, it is necessary to recycle it in order to reduce costs. 
Moreover, a comparison of cross section data between the two 
reaction routes points out a good yield for the 64Ni(d,2n) reaction 
with a thinner deposit of 64Ni, which reduces cost too [19]. The 
physical characteristics of these two isotopes are given in Table 2.
Radiopharmaceutical labelling
To date, the most commonly used route for radiolabelling 
of 3-[18F]fluoro-1-(2’-nitro-1’-imidazolyl)-2-propanol (=[18F]-
fluoromisonidazole) is the nucleophilic substitution of the 
tosylate-leaving group by no-carrier added [18F]-fluoride of the 
tetrahydropyranyl-protected precursor 1-(2’-nitro-1’-imidazolyl)-
2-O-tetrahydropyranyl-3-O-toluenesulphonylpropanediol (NITTP), 
followed by the hydrolysis of the protecting group with 1M HCl [20]. 
The synthesis procedure is summarized in Figure 3A.
The classical way to prepare [64Cu]-diacetyl-bis(N4-methyl-
thiosemicarbazone) (= [64Cu]-ATSM) is the addition of 1.5 ml of 
1 M sodium acetate on the dry residue of purified copper chloride 
(CuCl2) followed by the addition of H2-ATSM in DMSO [21]. The 
synthesis procedure is summarized in Figure 3B.
In terms of international pharmaceutical regulations, both 
chemical precursors (NITTP and H2-ATSM are considered as raw 
materials) for radiolabelling can be purchased from companies that 
manufacture these products according to good manufacturing 
practice requirements for active pharmaceutical ingredients for 
use in clinical trials (International Conference on Harmonisation 
Q7 chapter 19). 
Currently the two radiopharmaceuticals can be prepared 
by a fully automated procedure in sufficient amounts for clinical 
practice, with a radiochemical purity greater than 95%, giving 
a final product that fulfils the criteria of radiopharmaceutical quality 
(in terms of radionuclidic purity, sterility, and bacterial endotoxin 
analysis) [20, 21].
Pharmacological mechanism of radiotracer uptake
Both radiopharmaceuticals are lipophilic compounds which, 
therefore, diffuse rapidly through cell membranes. The two 
mechanisms of intracellular accumulation are presented in 
Figure 4.
Briefly, after entering a viable cell, nitroimidazole compounds, 
like [18F]-FMISO, are reduced to RNO2 radicals, regardless of 
the intracellular oxygen level. In the presence of oxygen, the 
radical is immediately reoxidized, and [18F]-FMISO leaves the 
cell. However, if the intracellular oxygen concentration is low, the 
RNO2 radicals are further reduced to RNHOH compounds that 
bind covalently to intracellular macromolecules and remain within 
the cell [22, 23].
[64Cu]-ATSM
[18F]-FMISO
A
Figure 3A. Radiolabelling of 18F-MISO; B. Radiolabelling of 64Cu-ATSM.
NITTP THP-protected
[18F]-FMISO
B
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The retention mechanism of [64Cu]-ATSM in hypoxic 
cells has been explored by several groups in the world. The latest 
development in the elucidation of the pharmacological mechanism 
is the following. The reduction of [Cu(II)-ATSM] complex by intracel-
lular thiols takes place in both normoxic and hypoxic cells resulting 
in an unstable [Cu(I)-ATSM]- complex. The lowest lipophilicity of 
this negatively charged complex increases its residence time 
within the cell [24]. In the presence of oxygen (normoxic cells), 
this unstable species is re-oxidised to a stable [Cu(II)-ATSM] 
complex and diffuses out of cells. Under hypoxic conditions, the 
[Cu(I)-ATSM]- complex slowly dissociates and copper is irrevers-
ibly trapped by intracellular copper chaperones proteins (Figure 4) 
[25–27]. In vitro studies have demonstrated that the accumulation 
time in normoxic cells was two to nine times lower than that in 
hypoxic cells, depending upon cell line [28]. This explains why, in 
clinical practice, despite the fact that the ATSM-copper complex 
is taken up in normoxic cells, a good image contrast is obtained.
Patient dosimetric data
The classical injected activity for a PET image of tumour hy-
poxia is about 3.7 MBq/kg (maximum 370 MBq) for [18F]-FMISO 
[29] and 925 MBq for [64Cu]-ATSM [30].
The comparative dosimetric data for internal organs obtained 
for the two radiotracers in men are given in Table 3 [31, 32] and 
show a twofold higher total body irradiation and 21-fold higher 
liver irradiation for [64Cu]-ATSM than [18F]-FMISO. These rela-
tively high dosimetric values for a diagnostic protocol are in the 
same order of magnitude as the total body dosimetry observed 
with thallium-201 in stress and rest cardiac imaging [33] and the 
liver irradiation observed for an abdomen multidetector CT scan 
procedure (11.5 mSv for a tissue weighting factor of 0.04) [34].
Clinical imaging of hypoxia
The first report on the use of [18F]-FMISO in humans was pub-
lished in 1992 for three patients with malignant glioma [35]. In 1996, 
a study assessed the level of hypoxia in a variety of human can-
cers (37 patients with non-small cell lung cancer, head and neck 
tumours, prostate tumours, cervical carcinoma, rectal carcinoma, 
metastatic breast carcinoma, thyroid carcinoma, or metastatic 
renal cell carcinoma) and concluded that human tumour hypoxia 
was widely prevalent and highly variable between tumours with 
the same histology and also between regions within the same 
tumour [36]. Tissue hypoxia has been determined by PET imaging 
and quantified in terms of contrast based on tissue-to-blood ratio 
(T/B) higher than 1.2, 2 hours after radiopharmaceutical adminis-
tration [37]. Different studies compared [18F]-FMISO uptake with 
pO2 measurement from an “Eppendorf electrode” and confirmed, 
with a good correlation, the use of [18F]-FMISO PET to measure 
hypoxia in renal cell carcinoma and head and neck cancer but not 
on human soft tissue tumours [38]. Several clinical studies have 
used [18F]-FMISO as a prognostic indicator for the survival of 
a number of patients. The kinetic behaviour of [18F]-FMISO in 
tumour tissue allowed a good prediction of patient outcome after 
radiotherapy and prediction of freedom from disease as well 
as overall survival [39].
Table 3. Comparative patient dosimetric data for [18F]-FMISO [31] 
and [64Cu]-ATSM [32]
Target organ [18F]-FMISO [mGy/MBq] [64Cu]-ATSM [mGy/MBq]
Liver 0.0183 0.390
Kidneys 0.0157 0.088
Spleen 0.0163 0.047
Gallbladder 0.0148 0.068
Adrenals 0.0166 0.032
Heart wall 0.0185 0.029
Pancreas 0.0179 0.056
Upper large 
intestine
0.0140 0.022
Lungs 0.0099 0.021
Stomach 0.0126 0.021
Total body 0.0126 0.026
Equivalent dose 
[mSv/MBq]
0.0140 0.036
Figure 4. Penetration and intracellular metabolic ways of 18F-MISO (left) and 64Cu-ATSM (right).
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The utilization of [64Cu]-ATSM is more recent. The first use 
in a human clinical trial was published in 2000 for patients with 
lung cancer, and an intense uptake was observed in all can-
cer patients [40]. For [64Cu]-ATSM, a good image contrast 
was obtained to a tissue-to-muscle ratio (T/M) threshold of 3.5. 
This threshold value differentiated patients whose cancer did 
not recur from those who developed a recurrence after complete 
therapy [41]. A PET study conducted in patients suffering from 
cervical cancer comparing [64Cu]-ATSM uptake with tissue mo-
lecular markers of hypoxia (vascular endothelial growth factor, 
cyclo-oxygenase-2, epidermal growth factor, carbonic anhydrase 
IX) confirmed a good correlation between quantitative PET im-
age and overexpression of the hypoxia molecular factors [42]. 
In 2001, a study successfully used the ability of [64Cu]-ATSM to 
delineate hypoxic regions of tumours prior to performing opti-
mal intensity-modulated radiation therapy (IMRT) by delivering 
a higher dose of radiation to hypoxic regions of the tumour while 
protecting the healthy margin in the head and the neck of cancer 
patients [43]. [64Cu]-ATSM has been used in some clinical PET 
studies and has shown high contrasts levels between hypoxic 
and normoxic tissues 10–15 minutes post injection, and provided 
clinically relevant information in terms of chemo/radio-resistance 
in different tumour sites, such as lung, rectal, or cervical carci-
nomas (images obtained with 60Cu-ATSM and confirmed with 
64Cu-ATSM [44, 45]). Some authors observed variations in image 
uniformity that could be related to the uptake site (cytosol or 
mitochondria) or to cell-to-cell biochemistry variations (glyco-
lysis or oxidative reduction pathway). The origin of this cellular 
accumulation variability is actually unknown but may provide, in 
the future, information about the phenotype of the cancer cell 
and finally on the patient outcome [24, 41].
Discussion/Conclusions
The two radiotracers of tumour hypoxia may be obtained with 
an easy and safe radiolabelling procedure in sufficient a amount for 
clinical practice. In terms of isotope physical properties, fluorine-18 
and copper-64 present the same maximal positron energy, which 
results in similar close intrinsic image resolution. However, cop-
per-64 presents a longer half-life, which permits easier logistics for 
PET centres distant from the production cyclotron. Copper-64 
production is accessible to a large number of medical cyclo-
trons that have the possibility to irradiate solid targets. The major 
drawback of copper-64 is the associated emission of b- (38.5%), 
which associates [64Cu]-ATSM with a less favourable dosimetry 
in comparison to [18F]-FMISO.
Studies using [18F]-FMISO have demonstrated a certain vari-
ability, with significant levels of hypoxia in several cancer types but 
failed to gain wider acceptance for routine clinical application 
because of a number of limitations, such as: 
—  slow accumulation in hypoxic tumours; 
—  low tumour-to-background ratios due to non-specific binding 
resulting from its relatively high lipophilicity; 
—  significant non-oxygen dependent metabolism leading to 
a considerable amount of radioactive metabolites; 
—  intra-tumoural large uptake variability.
In conclusion, [64Cu]-ATSM has several advantages over 
other radiopharmaceuticals used for PET of hypoxia, including 
a simple and rapid method for radiolabelling, faster clearance 
from normoxic tissues (allowing a short time between injection 
and imaging), a simple method for quantification, and very good 
image quality. In various clinical trials, [64Cu]-ATSM provided 
images of tumour hypoxia that improved the clinical outcome of 
patients submitted to external beam radiotherapy. The sum of these 
advantages seems to overcome the less favourable dosimetry of 
this radiopharmaceutical, and — in conclusion — [64Cu]-ATSM 
seems to be a good radiopharmaceutical candidate that can be 
used to obtain high quality images of tumour hypoxia.
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